Precision BioSciences, Inc. Common Stock (DTIL) Stock
Key stats
- Market cap
- $349.26M
- Price / Earnings ratio
- -6.9x
- EPS (TTM)
- $0.29
- Volume
- Loading
- 52-week high
- $11.29
- 52-week low
- $3.53
Source: third-party data provider, as of November 13, 2026
Compare with DTIL
Recent news

Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update
DTIL

Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026
DTIL

Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
DTIL

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
DTIL
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 62.95
- MACD 12/26/9
- 0.78
- EMA 9 of MACD
- 0.49
- MACD histogram
- 0.28
- SMA 50
- $7.00
- Price above SMA 50
- EMA 50
- $7.40
- Price above EMA 50
- SMA 200
- $6.73
- Price above SMA 200
- EMA 200
- $6.50
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update
DTIL

Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026
DTIL

Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
DTIL

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
DTIL

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
DTIL

Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
DTIL

Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
DTIL

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DTIL

Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?
Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?
DTIL

Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
DTIL
News tone: automated (AI) classification of the article's content, not a price prediction.
About Precision BioSciences, Inc. Common Stock
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael Amoroso | President, CEO & Director | 1978 |
| Mr. John Alexander Kelly R.Ph. | Chief Operating Officer | 1967 |
| Mr. Naresh Tanna | Chief Financial Officer | 1981 |
| Mr. Dario Scimeca J.D. | Chief Legal Officer & Secretary | 1975 |
| Dr. Jefferson J. Smith Ph.D. | Co-Founder & Chief Research Officer | 1973 |
| Ms. Mei Burris | VP of Finance & Chief Accounting Officer | 1986 |
| Dr. Cassie Gorsuch Ph.D. | Chief Scientific Officer | — |
| Ms. Juli Blanche | Chief People Officer | — |
| Ms. Cindy Atwell | Chief Development Officer | — |
| Mr. Neil Leatherbury M.S. | Senior VP and Head of Chemistry, Manufacturing & Controls | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 62.95
- MACD 12/26/9
- 0.78
- EMA 9 of MACD
- 0.49
- MACD histogram
- 0.28
- SMA 50
- $7.00
- Price above SMA 50
- EMA 50
- $7.40
- Price above EMA 50
- SMA 200
- $6.73
- Price above SMA 200
- EMA 200
- $6.50
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +16.6 | -11.3 | +8.2 | -18.1 | +11.5 | +31.7 |



